Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1662-6575|10|2|683-688

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.10, Iss.2, 2017-08, pp. : 683-688

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparing single‐agent with doublet chemotherapy in first‐line treatment of advanced non‐small cell lung cancer with performance status 2: A meta‐analysis

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 3, 2015-09 ,pp. : 253-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chemotherapy in Elderly Patients with Advanced Lung Cancer Part II: Treatment of Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 27, Iss. 6, 2004-12 ,pp. : 583-588

Karger

Access to resources Recommend Favorite

Gender Differences in Treatment Outcomes among Patients with Non-Small Cell Lung Cancer Given a Combination of Carboplatin and Paclitaxel

By  

Oncology, Vol. 75, Iss. 3-4, 2008-10 ,pp. : 169-174

Karger

Access to resources Recommend Favorite

Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 1, 2017-01 ,pp. : 51-58

Bentham Science Publishers

Access to resources Recommend Favorite

Elderly Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 198-203

Karger

Access to resources Recommend Favorite